What is dBMEDx?
Founded in 2010, dBMEDx operates at the intersection of medical diagnostics and automated engineering. The company is best known for the BBS Revolution, a pioneering bladder scanner that utilizes fully automatic technology to eliminate the need for manual aiming. By integrating wireless operation and automated self-diagnostics, dBMEDx addresses key pain points in clinical settings, specifically regarding diagnostic accuracy and the mitigation of cross-contamination risks. Their market position is defined by a commitment to user-friendly, high-efficiency medical devices that empower healthcare professionals to deliver superior patient outcomes through rapid, reliable data acquisition.
How much funding has dBMEDx raised?
dBMEDx has raised a total of $3.4M across 4 funding rounds:
Private Equity
$1.1M
Private Equity
$1.3M
Private Equity
$855K
Debt
$102K
Private Equity (2013): $1.1M, investors not publicly disclosed
Private Equity (2014): $1.3M, investors not publicly disclosed
Private Equity (2015): $855K, investors not publicly disclosed
Debt (2021): $102K featuring PPP
Key Investors in dBMEDx
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for dBMEDx?
With the recent infusion of capital, dBMEDx is well-positioned to accelerate its research and development pipeline and expand its footprint within the global healthcare market. The strategic focus will likely shift toward enhancing the interoperability of the BBS Revolution within existing hospital information systems and exploring new applications for their automated ultrasound platform. By leveraging this financial momentum, the company aims to solidify its competitive advantage, ensuring that its diagnostic solutions remain at the forefront of clinical innovation while scaling its manufacturing and distribution capabilities to meet the growing demand for automated point-of-care testing.
See full dBMEDx company page
